Journey Medical Corp (DERM)

NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA

Journey Medical Corp is a micro cap company (market value under $300 million) in the Drug Manufacturers - Specialty & Generic industry.

Journey Medical Corporation develops and distributes prescription dermatology treatments approved by the FDA across the United States. The company maintains a portfolio of eight medications addressing conditions including rosacea, acne, and hyperhidrosis, which it obtains through licensing arrangements and distributes through its own sales team. It operates as a subsidiary of Fortress Biotech, Inc.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Journey Medical Corp stock.

Our verdict on DERM

Overvalued: intrinsic value $2.60 per share, market price $3.90, margin of safety -49.8% (as of 2026-11-17).

A 1.1x revenue multiple, discounted for its losses, values the shares at $2.60; the price of $3.90 is 50% above that value.

ETFs with the most weight in DERM

1 more funds hold it; the full list is part of the paid plan.

More on DERM

Browse

Peers in Drug Manufacturers - Specialty & Generic

All 82 Drug Manufacturers - Specialty & Generic stocks

Cheaper than DERM in Drug Manufacturers - Specialty & Generic

17 more in this industry show a wider margin of safety.

Is DERM undervalued or overvalued?

DERM is overvalued (as of the 2026-11-17 close). A 1.1x revenue multiple, discounted for its losses, values the shares at $2.60; the price of $3.90 is 50% above that value.

What is the intrinsic value of DERM?

$2.60 per share (as of the 2026-11-17 close), against a market price of $3.90. That is a margin of safety of -49.8%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.